Sökning: "PRC2"
Visar resultat 1 - 5 av 21 avhandlingar innehållade ordet PRC2.
1. Towards forecasting epigenetic repression
Sammanfattning : Multicellular organisms form many different cell types from one genome, which requires differential gene activity. The Polycomb system upholds the correct gene expression programs by epigenetically silencing genes that encode critical transcription regulators. LÄS MER
2. Targeting molecular mechanisms for epigenetic silencing in multiple myeloma : Implications for biology and precision medicine
Sammanfattning : Multiple myeloma (MM) is a heterogeneous haematological cancer where malignant plasma cells clonally expand within the bone marrow. The transcriptional repressor PRC2 and its catalytic subunit EZH2 play a major role in MM, as PRC2 re-targeting results in a MM-specific gene silencing profile. LÄS MER
3. Genome-wide epigenetic profiling of B cell leukemia and lymphoma
Sammanfattning : Epigenetic modifications, at the level of DNA methylation and post-translational modifications of histone tails cooperatively function in the organization of the genome, and thereby establish the gene expression profiles, phenotypes, and cellular fates. In this work, we investigated the aberrant epigenome in chronic lymphocytic leukemia (CLL) which is one of the most frequent lymphoid malignancies in the west including the Nordic countries. LÄS MER
4. Methyltransferase Ash1, histone methylation and their impact on Polycomb repression
Sammanfattning : Antagonistic interactions between Polycomb Group (PcG) and Trithorax Group (TrxG) proteins orchestrate the expression of key developmental genes. Distinct maternally loaded repressors establish the silenced state of these genes in cells where they should not be expressed and later PcG proteins sense whether a target gene is inactive and maintain the repression throughout multiple cell divisions. LÄS MER
5. Targeted Inhibition of Polycomb Repressive Complexes in Multiple Myeloma : Implications for Biology and Therapy
Sammanfattning : Multiple myeloma (MM) is a hematological malignancy of antibody producing plasmablasts/plasma cells. MM is characterized by extensive genetic and clonal heterogeneity, which have hampered the attempts to identify a common underlying mechanism for disease establishment and development of appropriate treatment regimes. LÄS MER
